Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)
Risk Adapted Treatment for Primary AML in Adults, Based on Genetics and Minimal Residual Disease (MRD) in Patients up to the Age of 70 Years.
Sponsor: Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
A PHASE2 clinical study on Leukemia, Myelocytic, Acute, this trial is completed. The trial is conducted by Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias and has accumulated 6 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Oct 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Badalona, Spain , Barcelona, Spain , Girona, Spain , L'Hospitalet Del Llobregat, Spain , Lleida, Spain , Madrid, Spain , Murcia, Spain , Málaga, Spain , Palma de Mallorca, Spain and 6 more locations